Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents

Hao WANG; Yu YUAN; Bihao WU; Mingzhong XIAO; Zhen WANG; Tingyue DIAO; Rui ZENG; Li CHEN; Yanshou LEI; Pinpin LONG; Yi GUO; Xuefeng LAI; Yuying WEN; Wenhui LI; Hao CAI; Lulu SONG; Wei NI; Youyun ZHAO; Kani OUYANG; Jingzhi WANG; Qi WANG; Li LIU; Chaolong WANG; An PAN; Xiaodong LI; Rui GONG; Tangchun WU.
Frontiers of Medicine ; (4): 747-757, 2023.
Artículo en Inglés | WPRIM | ID: wpr-1010792

Documentos relacionados

  1. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents
  2. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents.
  3. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
  4. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.
  5. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.
  6. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals.
  7. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.
  8. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
  9. SARS-CoV-2 Omicron BA.1 breakthrough infection drives late remodeling of the memory B cell repertoire in vaccinated individuals.
  10. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.